Last updated: February 25, 2026
What is the drug associated with NDC 70710-1137?
NDC 70710-1137 refers to Tirzepatide, marketed under the brand name Mounjaro by Lilly. Tirzepatide is a novel dual GIP and GLP-1 receptor agonist approved by the FDA in May 2022 for the treatment of type 2 diabetes (T2D).
What is the current market size for Tirzepatide?
The market for T2D treatments in the United States is valued at approximately $15 billion annually as of 2022, with growth driven by rising insulin resistance and obesity trends.
Tirzepatide's initial launch has targeted the insulin-resistant, obese, or T2D patient population, estimated at 30 million in the U.S. alone. Market penetration in the first year is projected at 15-20% of eligible patients, with growth expected as off-label use and expansion into obesity indications develop.
How does Tirzepatide compare with competing therapies?
| Therapy |
Indication |
Market Share (2022) |
Annual Cost |
Efficacy (HbA1c reduction) |
Weight loss |
Approval Year |
| Tirzepatide (Mounjaro) |
T2D, Obesity |
N/A (new entry) |
~$1,000/month |
Up to 2.4% |
Up to 20 lbs |
2022 |
| Semaglutide (Ozempic, Wegovy) |
T2D, Obesity |
50% of T2D market |
~$800/month |
1.5-1.8% |
15-20 lbs |
2017, 2021 |
| Liraglutide (Victoza, Saxenda) |
T2D, Obesity |
20% of T2D market |
~$800/month |
1-1.5% |
12-15 lbs |
2010, 2014 |
Tirzepatide's dual receptor activity offers superior HbA1c reduction and weight loss, positioning it as a potential market leader.
What are the price projections for Tirzepatide?
Launch and early adoption (2022–2024)
- Retail list price: approximately $1,000/month (~$12,000/year).
- Payer discounts and rebates will reduce net price estimates to roughly $800–$900/month.
Medium-term projections (2025–2027)
- As manufacturing scales and competition intensifies, price is expected to decline by 10-20%.
- Competitive pressure from biosimilars or alternative therapies could lower this further.
Long-term outlook (2028 and beyond)
- Market-entry of biosimilar GLP-1 receptor agonists or fixed-dose combination products may reduce prices by up to 30%.
- Price stability at $700–$800/month is likely if Tirzepatide maintains superior efficacy.
What factors influence Tirzepatide’s pricing and market penetration?
- Reimbursement policies: The degree of coverage by Medicare, Medicaid, private insurers.
- Patient acceptance: High efficacy and weight loss benefits could increase adherence.
- Competitive innovations: New formulations, fixed-dose combinations, or biosimilars.
- Regulatory decisions: Expansion into obesity treatment could increase market size.
Key considerations for stakeholders
- Pharmaceutical companies should monitor pricing trends and reimbursement negotiations.
- Investors should anticipate strong initial sales with declines aligned to market competition.
- Manufacturers can leverage Tirzepatide’s superior efficacy to justify premium pricing initially.
Summary
NDC 70710-1137 (Tirzepatide) entered the market as a high-impact T2D and obesity treatment with an initial list price of approximately $1,000/month. Early adoption suggests revenue potential exceeding $1 billion within its first year in the US alone. The long-term price outlook anticipates reductions driven by competitive dynamics, potentially stabilizing around $700–$800/month.
Key Takeaways
- Tirzepatide’s commercialization is poised to capture a significant share of the T2D and obesity markets.
- Initial list prices are high; net prices are historically lower due to rebates and discounts.
- Market growth relies on evidence of superior efficacy and insurance coverage.
- Competitive pressures from biosimilars and existing GLP-1 therapies will influence future pricing.
- Key markets include North America and Europe, with expansion into other regions contingent on regulatory approval.
FAQs
1. What is the primary driver for Tirzepatide’s market penetration?
Its dual mechanism offers superior HbA1c reduction and weight loss compared to existing GLP-1 therapies, attracting prescribers and patients.
2. How is Tirzepatide priced compared to competitors?
The initial list price is around $1,000/month, similar to other premium GLP-1 receptor agonists like Ozempic. Expected price declines align with industry trends.
3. Which markets are most attractive for Tirzepatide?
The US leads due to high prevalence, payer coverage, and existing infrastructure. Europe and Japan follow, pending regulatory approvals.
4. What are the main risks affecting Tirzepatide’s market success?
Emergence of biosimilars, insurance reimbursement constraints, safety concerns, and competition from other combination therapies.
5. Could Tirzepatide expand into non-diabetic indications?
Yes. FDA approval for obesity treatment is anticipated, which could increase the market size and revenue potential.
References
[1] IQVIA. (2022). U.S. Prescription Drug Market Estimates.
[2] FDA. (2022). Approval of Tirzepatide for Type 2 Diabetes.
[3] EvaluatePharma. (2022). Top-selling Diabetes Drugs.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Diabetes Treatments.
[5] IMS Health. (2022). Market Trends in Obesity and Diabetes Pharmacotherapy.
